Source comparison
CJC-1295 FDA Approved Status: Comparison Table
FDA Approval Status Not approved. Classified as investigational research peptide Approved for pediatric growth hormone deficiency, adult GH deficiency, AIDS-related wasting, and other specific indications Approved specifically for HIV-associated lipodystrophy
This comparison does not assign a generated winner or score.
- FDA Approval Status
- Not approved. Classified as investigational research peptide
- Approved for pediatric growth hormone deficiency, adult GH deficiency, AIDS-related wasting, and other specific indications
- Approved specifically for HIV-associated lipodystrophy (excess abdominal fat)
- CJC-1295 lacks the regulatory oversight, safety verification, and post-market surveillance that approved therapies require. This is a categorical difference, not a technicality
- Manufacturing Standards
- No FDA batch-level oversight; synthesized by research peptide suppliers under state or no oversight
- cGMP (current Good Manufacturing Practice) standards enforced at every production batch; FDA facility inspections required
- cGMP standards with FDA-mandated potency and purity testing for every batch released to market
- Without FDA manufacturing oversight, CJC-1295 batches carry higher contamination risk, inconsistent potency, and no traceability if a safety issue emerges
- Clinical Trial Evidence
- Phase I and Phase II trials (small cohorts, 50–100 participants) demonstrating GH and IGF-1 elevation; no Phase III trials
- Phase III randomized controlled trials with 500–2,000+ participants proving efficacy and safety across multiple endpoints
- Phase III trials with 800+ participants demonstrating statistically significant reduction in visceral adipose tissue with acceptable safety profile
- CJC-1295's trial data is preliminary. It proves the peptide works biochemically but not that it is safe or effective for therapeutic use at population scale
- Legal Prescribing
- Cannot be legally prescribed by physicians; sold only under 'research use' exemptions
- Requires physician prescription; controlled under federal and state prescribing regulations
- Requires physician prescription with specific diagnostic criteria for lipodystrophy
- Purchasing CJC-1295 for personal use exists in a legal gray area. It is not technically illegal under federal law if sold 'for research,' but it circumvents the regulatory system designed to protect patients
- Post-Market Surveillance
- None. No adverse event reporting system, no long-term outcome tracking
- FDA MedWatch adverse event reporting required; manufacturers must report safety signals and conduct post-market studies if required
- FDA-mandated REMS (Risk Evaluation and Mitigation Strategy) for certain indications; ongoing safety monitoring
- If a serious adverse event occurs with CJC-1295, there is no centralized reporting mechanism and no regulatory body tracking patterns. Users are on their own